BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402

News   Sep 23, 2009

 
BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402
 
 
 

RELATED ARTICLES

How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?

News

Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?

READ MORE

Trispecific Antibodies Protect Against HIV

News

A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived.

READ MORE

Drug Discovery Alliance Formed to Help Increase Drug Development Success Rate

News

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE